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Abstract
Viral protein U (Vpu) is a type 1 membrane-associated accessory protein that is unique to human
immunodeficiency virus type 1 (HIV-1) and a subset of related simian immunodeficiency virus (SIV). The Vpu
protein encoded by HIV-1 is associated with two primary functions during the viral life cycle. First, it contributes to
HIV-1-induced CD4 receptor downregulation by mediating the proteasomal degradation of newly synthesized CD4
molecules in the endoplasmic reticulum (ER). Second, it enhances the release of progeny virions from infected cells
by antagonizing Tetherin, an interferon (IFN)-regulated host restriction factor that directly cross-links virions on host
cell-surface. This review will mostly focus on recent advances on the role of Vpu in CD4 downregulation and
Tetherin antagonism and will discuss how these two functions may have impacted primate immunodeficiency
virus cross-species transmission and the emergence of pandemic strain of HIV-1.
Introduction
HIV-1 interaction with host target cells is complex with
nearly every step of the virus infection cycle relying on
the recruitment of cellular proteins and basic machi-
neries by viral proteins [1]. For instance, the Tat regula-
tory protein recruits the pTEFb complex during viral
transcription to enhance host RNA polymerase II proces-
sivity and promote efficient elongation of viral transcripts
(reviewed in [2]). Similarly, the p6 domain of the Gag
structural protein interacts with the ESCRT complex
during viral assembly to direct the budding of progeny
virions (reviewed in [3]). Recent discoveries have shed
light on an additional level of complexity involving host
proteins that provide considerable resistance to infection
by HIV-1 and other viruses via cell-autonomous mechan-
isms that are likely part of the antiviral innate immune
response. As a virus which induces a persistent infection,
HIV-1 has evolved countermeasures to overcome the
antiviral activity of these host factors, also called restric-
tion factors, mainly through the activities of a set of viral
accessory proteins that include the Vif, Vpr, Vpu and Nef
proteins. These accessory proteins, which have been
recently the subject of intense research and progress,
represent one of the defining features of primate immu-
nodeficiency viruses. They are not commonly found in
other retroviruses and as such are likely to play a key role
in HIV-1 pathogenesis. Overall, it is becoming increas-
ingly clear that the function of these non-enzymatic viral
proteins is to modulate the cellular environment within
infected cells to promote efficient viral replication, trans-
mission and evasion from innate and acquired immunity
(for recent reviews [4,5]). In this review, we will focus on
the recent progress in our understanding of the functions
a n dm o d eo fa c t i o no ft h eH I V - 1V p ua c c e s s o r yp r o t e i n
and relate these to the pathogenesis of the virus as well
as the emergence of pandemic HIV-1 strains. Further-
more, we will highlight some important questions for the
future.
The vpu gene product
Vpu was initially identified as the product of an open
reading frame (ORF), referred as the U ORF (initially all
HIV-1 ORFs were designated by alphabetical letters)
located between the first exon of the tat and env genes
of HIV-1 [6,7]. The vpu gene is present in the genome
of HIV-1 but is absent from HIV-2 and other related
SIVs, such as SIV from sooty mangabey (SIVsmm) and
SIV from rhesus macaques (SIVmac) [6,7]. Structural
homologues have been detected in SIV from chimpan-
zee (SIVcpz), the precursor of HIV-1, and in SIVs from
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any medium, provided the original work is properly cited.the mona monkey (Cervicopithecus mona;S I V m o n ) ,t h e
greater spot-nosed monkey (Cercopithecus nictitans;
SIVgsn), the mustached monkey (Cercopithecus cephus;
SIVmus) and more recently in Dent’sm o n am o n k e y
(Cercopitheus mona denti; SIVden) and gorilla (Gorilla
gorilla; SIVgor) [8-13].
The Vpu protein encoded by HIV-1 is a 77-86
amino-acids membrane-associated protein capable of
homo-oligomerization [14]. The protein is translated
from a Rev-dependent bicistronic mRNA, which also
encodes the viral envelope glycoprotein (Env), suggest-
ing that expression of Vpu and Env are coordinated
during HIV-1 infection [15]. The protein is predicted
to have a short luminal N-terminal domain (3-12
amino acids), a single transmembrane (TM) spanning
domain that also serves as an uncleaved signal peptide
(23 amino acids) and a charged C-terminal hydrophilic
domain of 47-59 residues that extends into the cyto-
plasm [14,16] (Figure 1A). While the crystal structure
of the entire Vpu protein has yet to be solved, the
molecular structure of the N-terminal domain (resi-
dues 2-30) has been determined by nuclear magnetic
resonance (NMR) and found to contain a TM a-helix
spanning residues 8 to 25 with an average tilt angle of
13 degrees [17,18]. Interestingly, modeling as well as
biochemical and genetic evidence have suggested that
the TM domain is critical for Vpu oligomerization and
that a pentameric structure for the TM domain would
be optimal for the formation of an ion channel [19,20].
In that regard, several studies have suggested that Vpu,
like the M2 protein of influenza, may have an ion
channel activity (for a recent review [21]). However,
whether the ion channel activity of Vpu is required for
Vpu function is still controversial. NMR analysis of the
cytosolic domain, on the other hand, revealed that this
part of the protein comprises two a-helical regions
interconnected by a flexible loop containing a highly
conserved sequence (DSGNES) [16,22,23], which
includes a pair of serine residues (S52 and S56)
that are phosphorylated by casein kinase II [24-27]
(Figure 1).
HIV-1 Vpu proteins encoded by subtype B strains
appear to be largely expressed on intracellular mem-
branes, which correspond to the ER, the trans Golgi
network (TGN) as well as endosomal compartments,
but no accumulation of the protein is readily detected at
the cell surface [28-30]. Unlike the better-studied HIV-1
subtype B Vpu proteins, subtype C and SIVcpz Vpu
alleles fused to EGFP were reported to be transported to
the plasma membrane [31-33]. Interestingly, as depicted
in Figure 1B, amino acid sequence analysis of the cyto-
solic domain of HIV-1 Vpu reveals the presence of puta-
tive trafficking signals that harbor a degree of amino
acid variation among Vpu alleles from different subtypes
[34]. These trafficking signals include: 1) an overlapping
tyrosine (YXXF where F designs a hydrophobic resi-
due) and an acidic/dileucine based ([D/E]XXXL[L/I/V])
sorting motifs in the hinge region between the TM
anchor and the cytosolic domain, normally implicated in
endocytosis as well as in the targeting of TM proteins to
lysosomes and lysosome-related organelles [35]; 2)
another acidic/dileucine sorting signal, [D/E]XXXL[L/I/
V], in the second a-helix of the Vpu cytoplasmic tail
[32] (Figure 1B). The fact that several laboratory-
adapted strains and primary isolates of HIV-1 harbor
vpu genes with polymorphism at the level of these puta-
tive trafficking signals [29,34] raises the possibility that
regulation of Vpu subcellular localization and perhaps
biological activities may indeed confer the virus a selec-
tive advantage in some physiological conditions.
Studies mostly performed with Vpu originating from
subgroup B laboratory-adapted strains (NL4-3, BH10)
have established two main functions during infection of
Figure 1 Schematic representations of Vpu.( A )P r e d i c t e d
secondary and tertiary structure of Vpu showing the N-terminal
transmembrane domain (TM) and the two a-helices of the
cytoplasmic (CYTO) domain. The numbers indicate amino acid
positions of the NL4.3 prototypical Vpu allele. In both panels, yellow
circles represent phosphorylated serine residues (S52 and S56) sites.
The 13° tilt angle of the TM domain is indicated. (B) Vpu topology
with the corresponding HIV-1/SIVcpz Ptt Vpu consensus sequences
(HIV sequence database, http://www.hiv.lanl.gov). Question marks
indicate residues with no consensus available. The red box indicates
the conserved sequences recognized by b-TrCP. The blue boxes
highlight areas containing putative trafficking signals shown below.
X and F correspond to variable and hydrophobic amino-acid
residues, respectively. aH: a-helix.
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induces a rapid degradation of newly synthesized CD4
receptor molecules in the ER via the ubiquitin-proteasome
system [36,37]. In addition to its effect on CD4 catabolism,
Vpu promotes the release of progeny virions from HIV-1-
infected human cells [7,26,28,38-40] by counteracting
Tetherin (also designated BST2, CD317 and HM1.24), a
host restriction factor that strongly inhibits the release of
virions from the host cell surface [41,42].
Role of Vpu in HIV-1-induced CD4 receptor
downregulation
Expression of CD4 molecules at the surface of HIV-1
infected cells is detrimental to efficient viral replication
and spread
The process of HIV-1 entry into target cells begins with
the binding of the viral envelope glycoprotein gp120 to
both the CD4 receptor and one of the chemokine co-
receptors, CXCR4 or CCR5 [43]. Despite the critical
role played by the CD4 receptor during viral entry, it is
well established that an early and lasting effect of infec-
tion is the downregulation of the CD4 receptor from
the host cell surface. In fact, it appears that once viral
entry has occurred, continuous expression of the CD4
receptor may be detrimental to efficient viral replication
and spread. Early work on this issue has shown that
newly synthesized CD4 molecules are capable of retain-
ing the Env precursor proteins in the ER through their
high Env binding affinity, therefore preventing transport
and processing of mature Env products, gp120 and
gp41, to the site of virus assembly [44-47]. Additionally,
expression of CD4 at the cell surface promotes superin-
fection of cells by cell-free and cell-associated viruses
[48] and can interfere with the efficient release of infec-
tious progeny virions from the cell surface [49-54].
While the disadvantageous effect of CD4 on the release
and infectivity of cell-free virus is well established, it is
unclear whether the expression of CD4 at the cell sur-
face of infected cells also impedes cell-to-cell viral trans-
mission through virological synapses, a mode of
propagation that is believed to promote efficient viral
dissemination [55,56]. Despite its compact genome,
HIV-1 devotes two accessory proteins, Nef and Vpu, to
the task of suppressing expression of its primary recep-
tor. Early in infection, Nef removes mature CD4 mole-
cules that are already present at the cell surface by
enhancing their endocytosis by a pathway involving cla-
thrin and AP2 [57-59] followed by delivery of interna-
lized CD4 to the multivesicular body pathway for
eventual degradation in the lysosomes [60,61]. In con-
trast, Vpu, which is expressed late during the virus life
cycle, acts on newly synthesized CD4 molecules in the
ER and as such counteracts their effects in the early bio-
synthetic pathway [62]. This functional convergence,
involving two viral proteins acting on CD4 molecules
located in different cellular compartments and operating
by distinct mechanisms, implies that cell surface CD4
downregulation must play an important role for HIV-1
replication and propagation.
Vpu hijacks the host ubiquitin machinery to target CD4
for proteasomal degradation
The degradation of CD4 mediated by Vpu involves mul-
tiple steps that are thought to be initiated by the physi-
cal binding of Vpu to the cytoplasmic tail of CD4 in the
ER. Mutational and deletion analyses of CD4 have deli-
neated a domain of the molecule, encompassing residues
414 and 419 (LSEKKT) as well as an a-helix located in
the membrane proximal region of the viral receptor
cytosolic region, that are required for Vpu binding and
CD4 degradation [63-67] (Figure 2). The domain of Vpu
that is interacting with the cytosolic region of CD4 is
still not precisely defined but previous studies have
shown that these binding determinants are likely to be
present in the cytoplasmic region of the protein [68]. In
support of this finding, a mutant of Vpu that harbored a
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Figure 2 Model of Vpu-mediated CD4 degradation.F i r s t ,V p u
retains CD4 in the ER through TM domains interactions; formation
of Env/CD4 complexes could contribute to this retention. In
addition, CD4 and Vpu also interact through their cytosolic domains.
The minimal region of the CD4 cytoplasmic tail conferring Vpu
sensitivity was mapped to the region 414-LSEKKT-419. Recruitment
of the SCF
b-TrCP E3 ubiquitin ligase complex by Vpu is mediated by
interactions of phosphoserines in Vpu and the WD boxes of b-TrCP.
Interactions between Vpu and CD4 result in the trans-ubiquination
of the cytosolic tail of CD4 on lysine, serine and threonine residues.
These ubiquitination events might further contribute to CD4
retention in the ER but, importantly, target CD4 for degradation by
the cytosolic proteasome. This targeting involves a dislocation step
mediated by the p97-UFD1L-NPL4 complex, a critical component of
ERAD. This complex recognizes K48-linked polyubiquitinated chains
on the cytosolic tail of CD4 through the UFD1L co-factor. The p97
protein via its ATPase activity subsequently directs the dislocation of
CD4 across the ER membrane where the receptor becomes readily
accessible for proteasomal degradation.
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still able to bind CD4 and mediate its degradation as
well as its wild-type (WT) counterpart [69]. Further-
more, mutational analysis of the Vpu cytoplasmic
domain revealed that the first a-helix was structurally
important for CD4 binding and degradation [70,71].
Although the binding of Vpu to CD4 is necessary to
induce CD4 degradation, it is not sufficient. Phosphory-
lation-deficient mutants of Vpu were shown to be
unable to induce CD4 degradation while interacting
with CD4 as efficiently as their WT counterpart
[26,63,68,72,73]. A major finding in the mechanism
underlying Vpu-mediated CD4 degradation was the dis-
covery that phosphorylated Vpu proteins interacted with
b-TrCP-1 [73] and b-TrCP-2 [74], two paralogous F-box
adaptor proteins that are part of the cytosolic Skp1-Cul-
lin1-F-Box (SCF) E3 ubiquitin (Ub) ligase complex [73].
b-TrCP functions as a substrate specificity receptor for
the SCF
b-TrCP E3 Ub ligase and recognizes substrates,
such as Vpu, upon phosphorylation of the two serine
residues present within a conserved DS
PGFXS
P b-TrCP
recognition motif [75] (Figure 1B). By directly interact-
ing with the WD-repeat b-propeller of b-TrCP, Vpu is
able to form a CD4-Vpu-b-TrCP ternary complex and
as such brings CD4 and the other components of the E3
Ub ligase in close proximity so that trans-ubiquitination
of CD4 could occur (Figure 2). In fact, biochemical
and functional evidence in human cells as well as in
yeast S. cerevisiae expressing Vpu and CD4 revealed
that SCF
b-TrCP recruitment by Vpu results in polyubi-
quitination of the cytosolic tail of CD4 [76,77], thus
marking the viral receptor for degradation by the cyto-
s o l i cp r o t e a s o m e[ 3 7 , 7 8 ] .T h ef u n c t i o no fV p ui nC D 4
degradation is therefore very similar to that of E3 Ub
ligase adaptors which link substrates to Ub ligases. Both
b-TrCP1 and b-TrCP2 appear to be involved in the for-
mation of a functional Vpu-SCF
b-TrCP E3 Ub ligase
complex since small interfering (si) RNA silencing of
both genes simultaneously was required to fully reverse
Vpu-mediated CD4 degradation [74].
While the first helix of Vpu appears important for
CD4 binding, the role of the second helix remains
unclear. Deletion of the C-terminal 23 amino-acid resi-
dues or substitution of residues Val 64 to Met 70 abro-
gated Vpu-mediated CD4 degradation without, however,
affecting CD4 binding [31,71]. A more recent study ana-
lyzed systematically the importance of each amino-acid
within this region by alanine scan mutagenesis and iden-
tified Leu 63 and Val 68 as residues required for CD4
downregulation. Interestingly, in the case of Leu 63,
substitution of this residue with Ala or Val, which main-
tain the predicted secondary structure of the helix, did
not affect binding to CD4 or b-TrCP, but did abolish
CD4 downregulation [70], suggesting that binding of
Vpu to CD4 and recruitment of b-TrCP might not be
sufficient to induce CD4 degradation and consequently
that other process and/or interactions might be involved
in this mechanism. It is interesting to note that the con-
served Leu 63 and Val 68 are part of a conserved acidic/
dileucine sorting signal, [D/E]XXXL[L/I/V] (Figure 1B),
usually involved in the trafficking of membrane proteins
between the endosomes and the TGN. The role of this
sorting motif on Vpu exit from the ER as well as on its
trafficking in general still remains undefined.
ERAD-ication of CD4 by Vpu
The process of Vpu-mediated CD4 degradation is reminis-
cent of a cellular quality control process called ER-
associated protein degradation (ERAD) that eliminates
misfolded or unassembled proteins from the ER [79,80].
Abnormal proteins targeted by the ERAD pathway are
usually recognized by a quality control system within the
ER lumen and ultimately degraded by the cytoplasmic ubi-
quitin-proteasome system following transport across the
ER membrane by a process called dislocation. However,
unlike typical ERAD, which uses several membrane-bound
E3 Ub ligases, including the HRD1-SEL1L complex [81],
TEB4/MARCH-VI [82], and the GP78-RMA1 complex
[83], Vpu-mediated CD4 degradation relies on the cytoso-
lic SCF
b-TrCP E3 Ub ligase complex that is responsible for
ubiquitination and degradation of non-ERAD substrates
such as IB [84] and b-catenin [85]. Consistent with these
findings, genetic evidence in S. cerevisiae yeast expressing
human CD4 and HIV-1 Vpu revealed that CD4 degrada-
tion induced by Vpu did not require HRD1 (E3), SEL1L
and the E2 Ub conjugating enzyme UBC7, which are key
components of the machinery responsible for ubiquitina-
tion of most ERAD substrates [76].
Recent studies have dissected in molecular terms the
process of CD4 degradation mediated by Vpu and
found that although the mechanism is distinct from
typical ERAD it still shares similar features and, impor-
tantly, involves late stages components of the ERAD
pathway. As a first step, Vpu was found to target CD4
for degradation by a process involving polyubiquitina-
tion of the CD4 cytosolic tail by SCF
b-TrCP [76,77]
(Figure 2). Interestingly, replacement of cytosolic Ub
acceptor lysine residues reduced but did not abolish
Vpu-mediated CD4 ubiquitination and degradation, rais-
ing the possibility that the CD4 degradation induced by
Vpu is not entirely dependent on the ubiquitination of
cytosolic lysines [77]. Indeed, recent evidence revealed
that more profound inhibition of degradation could be
achieved by mutation of all lysine, serine and threonine
residues in the CD4 cytosolic tail ([86] and our unpub-
lished results). The ubiquitination process involved in
Vpu-mediated CD4 degradation, therefore, resembles
that involved in MHC-I downregulation induced by the
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ligase, which mediates ubiquitination of nascent MHC-I
heavy chain (HC) cytosolic tail via serine, threonine or
lysine residues to target MHC-I heavy chain for degra-
dation by ERAD [87]. As a second step, although Vpu
uses a non-ERAD E3 Ub ligase to induce CD4 degrada-
tion, it is co-opting downstream components of
the ERAD pathway. In fact, the VCP-UFD1L-NPL4
complex, a key component of the ERAD dislocation
machinery [88,89], was shown to be involved in CD4
degradation by Vpu (Figure 2). Using siRNA, a recent
study reported a requirement of the valosin-containing
protein (VCP) AAA ATPase p97 and its associated co-
factors UFD1L and NPL4 in Vpu-mediated CD4 degra-
dation [86]. Furthermore, the fact that mutants of p97
that are unable to bind ATP or to catalyze ATP hydro-
lysis exerted a potent dominant negative (DN) effect on
Vpu-mediated CD4 degradation indicated that the
ATPase activity of p97 was required for this process
[77,86]. Further dissection of the role of the UFD1L and
NPL4 cofactors in Vpu-mediated CD4 degradation
revealed that while p97 appears to energize the disloca-
tion process through ATP binding and hydolysis,
UFD1L binds ubiquitinated CD4 through recognition of
K-48 chains and NPL4 stabilizes the complex [86].
A role of the VCP-UFD1L-NPL4 complex in mediating
the extraction of CD4 from the ER membrane, as
observed for ERAD substrates [76] is consistent with
data showing that Vpu was promoting the dislocation of
ubiquitinated CD4 intermediates across the ER mem-
brane [76,77]. Vpu, therefore, appears to bypass the
early stages of ERAD including substrate recognition
and ubiquitination by ERAD machinery components,
but joins in the later stages beginning with dislocation
by the VCP-UFD1L-NPL4 complex (Figure 2).
Retention of CD4 molecules in the ER by Vpu?
Besides its role in CD4 ubiquitination and dislocation
across the ER membrane so that receptor molecules be
accessible to the cytosolic proteasome, a recent study
provided evidence that Vpu plays also a role in the
retention of CD4 in the ER [86]. It was initially found
that Vpu was targeting CD4 molecules that were
retained in the ER through formation of a complex with
Env [62]. However, Magadan and colleagues found that
even in absence of Env, large amounts of CD4 are
retained in the ER in the presence of Vpu when ERAD
is blocked [86]. Unexpectedly, these authors further
showed that this retention was independent of the only
interaction of Vpu and CD4 reported to date, which
involves the cytosolic domain of both proteins. Rather,
CD4 ER retention appeared primarily dependent on
direct or indirect interactions involving the TM domains
of both CD4 and Vpu. Indeed, a Vpu mutant containing
a heterologous TM domain from the G glycoprotein of
vesicular stomatitis virus (VSV) failed to retain CD4 in
the ER. Although these results support a role of TM
domain interactions in the retention of CD4 in the ER
by Vpu, this interaction does not appear to rely on Vpu
TM primary sequences since a Vpu mutant containing a
scrambled TM domain was still competent at binding
CD4 and at mediating CD4 degradation [69]. Vpu-
mediated ubiquitination appears also to contribute to
CD4 retention in the ER, but the mechanism remains
unclear. Therefore, it appears that Vpu retains CD4 in
the ER by the additive effects of two distinct mechan-
isms: assignment of ER residency through the TM
domain and ubiquitination of the cytosolic tail. The
findings of Magadan and colleagues supporting a role of
V p ui nt h er e t e n t i o no fC D 4i nt h eE Ra r en o te n t i r e l y
consistent with those of a previous report, which
showed that CD4 can efficiently traffic to the Golgi
complex in presence of Vpu when CD4 is not retained
in the ER by Env [36]. Indeed, using a subviral construct
expressing Vpu and a mutant of gp160 defective for
CD4 binding, Willey and colleagues found that despite
the presence of Vpu the majority of CD4 acquired Endo
H-resistant complex carbohydrates in the Golgi appara-
tus within 60 minutes after synthesis. Whether this dis-
crepancy results from a difference in Vpu expression
levels (Willey et al. expressed Vpu from a subviral vec-
tor while Magadan et al. used a codon-optimized Vpu
construct that expresses much higher levels of the pro-
tein) or from differences in the assays used (prevention
of CD4 degradation by blocking ERAD vs. allowing traf-
ficking of CD4 by not blocking the receptor exit from
the ER with Env) remains unclear. Clearly, more studies
will be required to fully understand the mechanism
through which Vpu confers on CD4 an intrinsic propen-
sity to reside in the ER. Importantly, it will be critical to
assess its relevance and contribution in the context of
HIV infection where large amounts of CD4 are already
complexed to Env gp160 in the ER.
Overall, based on previousf i n d i n g sa n dm o r er e c e n t
evidence, a model of Vpu-mediated CD4 degradation
emerges whereby Vpu might exert two distinct separable
activities in the process of downregulating CD4: reten-
tion in the ER followed by targeting to a variant ERAD
pathway (Figure 2).
Role of Vpu in HIV-1 release and transmission
Vpu promotes efficient release of HIV-1 particles in a cell-
type specific manner
In addition to its effect on CD4 catabolism, Vpu was
reported to promote the efficient release of virus parti-
cles from HIV-1-infected cells [7,38]. This finding was
supported by electron microscopy (EM) studies, which
revealed an accumulation of mature virions still tethered
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absence of Vpu [28,90]. Early studies demonstrated that
the need of Vpu for efficient HIV-1 particle release was
only observed in certain cell types. Notably, while Vpu-
deficient HIV-1 release was drastically reduced in HeLa
cells, monocyte-derived macrophages, and to a smaller
extent in primary CD4+ T cells, normal viral particle
release was observed in HEK293T, COS, CV-1, and
Vero cells [39,91,92]. Importantly, the fact that Vpu
could significantly enhance viral particle production by
Gag proteins from HIV-2 or retroviruses distantly
r e l a t e dt oH I V - 1 ,s u c ha sV i s n aa n dm u r i n el e u k e m i a
virus (MLV), suggested that the effect of Vpu was unli-
kely to require highly specific interactions with Gag pro-
teins, but rather was more consistent with a model
where Vpu enhanced retroviral release indirectly
through modification of the cellular environment [40].
Tetherin, the last obstacle to enveloped virus release
The notion that a cellular inhibitor of HIV-1 particle
release antagonized by Vpu could be responsible for the
inefficient release of Vpu-deficient HIV-1 in restrictive
cells was suggested by the observation that heterokar-
yons between restrictive HeLa and permissive COS cells
exhibited a restrictive phenotype similar to that dis-
played by HeLa cells [93]. Importantly, the fact that vir-
ions retained at the cell surface could be released by
protease treatment suggested that a protein expressed at
the cell surface was involved in the “tethering” of virions
to the cell surface as opposed to a budding defect that
prevented membrane separation [94]. Interestingly, cell
types that allowed efficient release of Vpu-deficient
HIV-1 viruses could become restrictive for viral release
after type 1 IFN treatment, thus suggesting that the
putative cellular protein that efficiently tethered virions
on host cell surface was induced by type I IFN [95].
Almost simultaneously, the Bieniasz and Guatelli
groups identified Tetherin as the cellular factor responsi-
ble for the inhibition of HIV-1 particle release and coun-
teracted by the Vpu accessory protein [41,42]. Both
groups found Tetherin to be constitutively expressed in
cell lines that required Vpu for efficient particle release,
like HeLa cells, but not in permissive HEK293T and
HT1080 cells. Likewise, expression of Tetherin and its
associated restrictive phenotype could be induced by
IFN-a in permissive HEK293T and HT1080 cells and
enhanced in Jurkat and primary CD4+ T cells. Further-
more, while introduction of Tetherin into HEK293T and
HT1080 cells inhibited HIV-1 particle release in absence
of Vpu, siRNA-directed depletion of Tetherin in HeLa
cells led to efficient release of Vpu-deficient HIV-1 parti-
cles [41,42]. In addition to HIV-1, Tetherin has been
shown to exert its antiviral activity against a broad range
of enveloped viruses, including many retroviruses
(alpharetrovirus, betaretrovirus, deltaretrovirus, lenti-
virus, and spumaretrovirus), filoviruses (Ebola and
Marburg viruses), arenaviruses (Lassa virus), paramyxo-
viruses (Nipah virus) as well as Kaposi Sarcoma Herpes
Virus (KSHV) [41,42,94,96-99], thus indicating that the
process of restriction is unlikely to involve specific inter-
actions with virion protein components.
Tetherin: expression, structure and trafficking
Tetherin is a protein highly expressed in plasmacytoid
dendritic cells (pDCs), the major producers of type I
IFN, and in some cancer cells, while lower basal levels
of expression are detected in bone marrow stromal cells,
terminally differentiated B cells, macrophages, and T
cells [100-104]. Its expression is strongly induced by
type I IFNs in virtually all cell types [99,101,105-107],
indicating that it is likely p a r to ft h ei n n a t ed e f e n s e
response to virus infections.
Tetherin is a glycosylated type II integral membrane
protein of between 28 and 36 kDa with an unusual
topology in that it harbors two completely different
types of membrane anchor at the N- and C-terminus. It
is composed of a short N-terminal cytoplasmic tail
linked to a TM anchor that is predicted to be a single
a-helix, a central extracellular domain predicted to form
a coiled-coil structural motif, and a putative C-terminal
glycophosphatidyl-inositol (GPI)-linked lipid anchor
[105,108,109] (Figure 3A). This rather atypical topology
is only observed in one isoform of the prion protein
[110]. As a GPI-anchored protein, Tetherin is found
within the cholesterol-enriched lipid domains from
which HIV-1 and other enveloped viruses preferentially
assemble and bud [108,111-113]. The protein is loca-
lized not only at the plasma membrane but also within
several endosomal membrane compartments, including
the TGN as well as early and recycling endosomes
[29,108,112,114]. Clathrin-mediated internalization of
human Tetherin is dependent upon a non-canonical tyr-
osine-based motif present in the cytoplasmic tail of the
protein (Figure 3B), which appears recognized by
a-adaptin but not the μ2-subunit of the AP-2 complex
as it was initially reported for the rat Tetherin [109,112].
Moreover, after endocytosis, Tetherin delivered to early
endosomes is subsequently transported to the TGN
through recognition of the cytoplasmic domain by the
μ1-subunit of the AP-1 complex [109], suggesting the
involvement of the sequential action of AP-2 and AP-1
complexes in internalization and delivery back of
Tetherin to the TGN. Although the current data is con-
sistent with a model whereby Tetherin continually cycles
between the plasma membrane and the TGN with a
fraction targeted for degradation, it still remains to be
determined whether the protein is indeed recycling from
the TGN to the cell surface. Interestingly, recent
Dubé et al. Retrovirology 2010, 7:114
http://www.retrovirology.com/content/7/1/114
Page 6 of 19findings from Rollason and colleagues revealed that
Tetherin localizes at the apical surface of polarized
epithelial cells, where it interacts indirectly with the
underlying actin cytoskeleton, thus providing a physical
link between lipid rafts and the apical actin network in
these cells [111]. Whether this property of Tetherin
relates to its activity as an inhibitor of HIV-1 release
remains unknown.
The Tetherin ectodomain contains two N-linked gly-
cosylation sites, three cysteine residues and a coiled-coil
motif that mediates homodimerization (Figure 3B).
Tetherin glycosylation was shown to be important for
proper transport and perhaps folding of the protein
[115]; but, however, appeared to be dispensable for its
activity as a restriction factor [97,115,116]. In contrast,
the presence of cysteine residues in the extracellular
domain of Tetherin was found required for the anti-
HIV-1 function of the protein, as mutation of all three
cysteine residues to alanine abrogated the antiviral activ-
ity without affecting Tetherin’s expression at the cell
surface [115,116]. In that regard, it has been proposed
that Tetherin forms a parallel dimeric coiled-coil that is
stabilized by C53-C53, C63-C63 and C91-C91 disulfide
bonds. Interactions within the coiled-coil domain and at
least one disulfide bond formation are required for
dimer stability and antiviral function [115,116]. Recently,
a partial structure of the extracellular domain of
Tetherin has been solved by X-ray crystallography by
three different groups [117-119]. All these studies sup-
port a model in which the primary functional state of
Tetherin is a parallel dimeric disulfide-bound coiled-coil
that displays flexibility at the N-terminus.
Tetherin directly cross-links HIV-1 virions on infected cell
surface
Accumulating evidence suggest that Tetherin prevents
viral release by directly cross-linking virions to host cell
membranes. Additionally, restricted mature virus parti-
cles can also be found within intracellular endosomal
structures [94], suggesting that following retention at
the plasma membrane, tethered particles could be inter-
nalized and perhaps targeted for degradation in late
endosomal compartments [120]. Consistent with a direct
tethering mechanism, immuno-EM studies revealed that
Tetherin is detected in the physical bridge between nas-
cent virions and the plasma membrane as well as
between virions tethered to each other [121,122]. In
fact, both biochemical and immuno-EM evidence indi-
cate that Tetherin is incorporated into virions
[114,115,121,122]. Importantly, the view that Tetherin
itself, without the need of any specific cellular cofactor,
is responsible for tethering virions on host cell surface,
is supported by evidence from the Bieniasz group. They
elegantly showed that protein configuration rather than
primary sequences is critical for the tethering pheno-
type. Indeed, an entirely artificial Tetherin-like protein
consisting of structurally similar domains from three
unrelated proteins (TM from transferrin receptor,
coiled-coil from distrophia myotonica protein kinase
and GPI anchor from urokinase plasminogen activator
receptor), inhibited the release of HIV-1 and Ebola
virus-like-particles in a manner strikingly similar to
Tetherin [115].
Although strong evidence for a direct tethering
mechanism exists, the precise topology of the Tetherin
dimers and the definition of the molecular interfaces
retaining nascent virions at the cell surface remain open
questions. For instance, it is not clear whether both
membrane anchors remain in a single membrane surface
and virions are retained by interaction between two
Tetherin ectodomains (Figure 4A) or, if both Tetherin
anchors can be incorporated in different membrane
Figure 3 Schematic representations of Tetherin. Secondary and
tertiary model of human Tetherin. Glycosylation sites at position 65
and 92 are shown as well as the GPI-anchor and the cytoplasmic,
transmembrane (TM) and extracellular coiled-coil domains. The
functional parallel dimeric state is shown here. (B) Tetherin
topology. An amino-acid sequence alignment of human,
chimpanzee, rhesus and African green monkey (agm) Tetherin
alleles is shown below. Hyphens and bold letters represent
respectively deletions and residues in human Tetherin under
positive selection. Putative Ub-acceptor residues, cysteine residues
involved in dimerization as well as N-glycosylation sites are labelled
in orange, pink and red, respectively. Putative trafficking signals, the
predicted transmembrane domain and the coiled-coil domain are
highlighted in blue, green and yellow. The sites of interaction
mapped for SIV Nef and HIV-1 Vpu are boxed in dark blue and dark
green, respectively. Note that the SIV Nef-interacting region is
deleted in human Tetherin. The site of cleavage prior to addition of
the GPI lipid anchor is represented by the dashed line.
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cytoplasmic tail or the GPI anchor abrogates the anti-
viral activity of Tetherin [41,115] supports a model
whereby Tetherin is a parallel homodimer with one set
of anchors in the host membrane and the other in the
virion membrane (Figure 4B). This data also suggest
that anti-parallel dimers with monomeric links to mem-
branes (Figure 4C) do not exist or cannot effectively
tether. It remains unclear whether the parallel dimers of
Tetherin that span the plasma and viral membranes
h a v eap r e f e r e n c ef o rw h i c hm e m b r a n ea n c h o re n d su p
in the cell membrane or in the virion although there is
some evidence that the TM anchor is favored in the
v i r u sm e m b r a n ea n dt h eT Ma n c h o ri nt h ec e l l[ 1 1 5 ] .
While this membrane spanning model is consistent with
the structural properties of Tetherin, there are, however,
two caveats to this model. First, treatment of tethered
virions with the GPI anchor-cleaving enzyme, phospha-
tidyl inositol-specific phospholipase C (Pi-PLC), did not
effectively release virions from the cell surface [122].
Second, based on the structural data, the maximum dis-
tance that can be bridged by Tetherin in the configura-
tion outlined in Figure 4 is about 17 nm [117-119].
However, the distance betw e e nt h ep l a s m am e m b r a n e
and tethered viral membranes observed in EM studies is
frequently significantly larger than that distance
[121,122]. One alternative model to the membrane
spanning domain model is that. individual Tetherin
monomers are anchored at both end to the viral or
plasma membranes but associates with each other
through dimers or higher order structures (Figure 4A).
Although this model explains a requirement for dimeri-
zation, it does not explain why Tetherin requires both
of its membrane anchor domains for its antiviral activity
[41,115]. Moreover, in this model, Tetherin would tether
virus particles quite close to the plasma membrane
(3-5 nm), a distance not supported by EM analysis
[41,115,121,122]. Clearly more studies are required to
fully understand how Tetherin dimers tether newly
formed virions to host cell surface.
Effect of Tetherin on HIV-1 cell-to-cell transmission
Increasing evidence suggests that HIV-1 can spread
directly between T cells by forming a polarized supra-
molecular structure termed a virological synapse,
whereby nascent virions are recruited to intimate adhe-
sive contacts between infected and uninfected cells
[55,56]. Since Vpu-deficient HIV-1 particles accumulate
at the cell surface as a result of Tetherin-mediated
restriction, it is unclear whether these restricted virions
can undergo cell-to-cell transfer or whether Tetherin
restricts spread via virological synapses in addition to
inhibiting the release of cell-free virions. Tetherin was
recently reported to inhibit productive cell-to-cell trans-
mission from Tetherin-positive donor cells (HEK 293T,
HeLa and T-cells) to target lymphocytes without pre-
venting the formation of virological synapses [123].
Interestingly, in the presence of Tetherin, Vpu-deficient
viruses accumulated at the synapses and were essentially
transferred to target cells as large abnormal aggregates.
These viral aggregates were found to be impaired in
their ability to fuse to target cells and as such did not
efficiently promote productive infection after transfer.
These findings contrast with results recently reported by
Jolly and colleagues which showed that Tetherin does
not restrict virological synapse-mediated T-cell to T-cell
transfer of Vpu-deficient HIV-1 [124]. In fact, this study
showed that in some circumstances Tetherin might pro-
mote cell-to-cell transfer either by mediating the accu-
mulation of virions at the cel ls u r f a c eo rb yr e g u l a t i n g
the integrity of the virological synapse. These latter find-
ings are consistent with a previous study that reported
that in vitro selection of HIV-1 to spread via cell-to-cell
contact in T-cell lines led to the emergence of viral var-
iants with mutations in both the Env and the Vpu pro-
teins [125]. Likewise, earlier observations showed that
WT and Vpu-deficient HIV-1 production usually peak
at the same time during a spreading infection even
though less Vpu-deficient virus is released in the extra-
cellular milieu [28,38]. The contrasting results obtained
by Jolly and colleagues [124] and Casartelli and collea-
gues [123] might reflect cell type dependent variations
in the levels of Tetherin expression since the two studies
used distinct Tetherin-expressing cell donor systems.
Parallel
Monomers are anchored in both membranes
A
anti-Parallel Each monomer is
anchored in a 
different membrane
C B
Figure 4 Schematic representations of possible direct tethering
modes. (A) Tethering by interaction via the ectodomains of Tetherin
dimers. One Tetherin molecule is inserted into the virus while the
other is anchored into the cellular membrane. (B) Tethering by
incorporation of one of the molecule anchors in the virus and the
other in the cellular membrane. Different options are shown,
including GPI anchors or transmembrane domains of parallel
Tetherin homodimers incorporated into a virion and (C) both type
of anchors from an antiparallel tetherin homodimer incorporated
into virion. The fact that deleting either the GPI anchor or the TM
domain prevents the restriction suggests that either configuration A
and C are not important contributors of the tethering process or
that a single tethering domain is not sufficient to retain virions at
the cell surface. Indeed, it is also conceivable that all these potential
configurations may contribute to the restrictive activity albeit to
different extent.
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conditions such as those prevailing in macrophages and
dendritic cells (DCs), HIV-1 cell-to-cell transmission
might be impaired, whereas at lower levels, such as in
T-lymphocytes, Tetherin may not restrict or may even
contribute to cell-to-cell transmission. In that regard,
Schindler and colleagues recently showed that a Vpu
mutant (S52A) that displayed an impaired Tetherin
antagonism was unable to replicate efficiently in macro-
phages, while it spread as well as the wild type virus in
ex vivo lymphoid tissue (HLT) or peripheral blood lym-
phocytes [103]. Therefore, one role of Vpu would be to
maintain a balance between cell-free and cell-to-cell
HIV-1 spread in the face of antiviral immune responses.
Potential roles of Tetherin in innate immunity
HIV-1 infection induces pDCs to produce a broad range
of type I IFN through the activation of Toll-like recep-
tors 7 and 9 (TLR7 and TLR9) [126,127]. Type I IFN
activates natural killer (NK) cells, myeloid DCs, T cells,
B cells, and macrophages and induces expression of sev-
eral hundreds of different IFN-stimulated genes, includ-
ing Tetherin. In turn, it was recently reported that
human Tetherin is the natural ligand for ILT7, a protein
that is expressed exclusively on pDCs [107]. Binding of
Tetherin to ILT7 was found to trigger a signaling path-
way that negatively modulates TLR7- or TLR9-mediated
type I IFN and proinflammatory cytokine secretion, thus
establishing a negative feedback loop in which IFN-
induced Tetherin binding to the ILT7-FcεRIg complex
signals the inhibition of additional IFN production
[107]. Therefore, in addition to its anti-viral function,
T e t h e r i nm i g h ta l s oh a v ear o l ei nm o d u l a t i n gp D C ’s
IFN responses as well as inflammatory responses to
virus infection. Whether or not Vpu interferes with this
Tetherin immunomodulatory function during HIV-1
infection remains an open question.
HIV-1 riposte to Tetherin-mediated restriction
How Vpu counteracts the antiviral activity of Tetherin
has attracted considerable attention since the discovery
of the restriction factor. A key observation made early
on was that Vpu downregulated Tetherin from the cell-
surface [42]. This reduction of Tetherin levels at the
cell surface correlated with the enhancement of HIV-1
particle release observed upon Vpu expression. Since
Tetherin restricts HIV-1 virus particle release at the
plasma membrane, removal of Tetherin from its site of
tethering action represents an intuitive model through
which Vpu could counteract this cellular restriction,
although this model has been challenged [102]. Reduc-
tion of Tetherin at the cell-surface is likely to prevent
cross-linking of cellular and viral membranes, which
implies that virions released from Vpu-expressing cells
would be devoid of Tetherin molecules. Although this
notion is supported by the decreased co-localization
between Tetherin and Gag in presence of Vpu
[41,96,128], biochemical analyses revealed that Vpu
expression decreases only partially Tetherin accumula-
tion in released virus particles [115,121,122]. Further-
more, immuno-EM studies showed that virions
produced from Vpu-expressing cells still incorporate
Tetherin albeit at a lower density [114,122]. These
results suggest that either a threshold level of virion-
associated Tetherin is required to mediate the restriction
or alternatively removal of Tetherin from specific
plasma membrane microdomains could underlie the
mechanism by which Vpu antagonizes Tetherin. In that
regard, Habermann and colleagues reported that Vpu
would be more efficient at downregulating Tetherin out-
side HIV-1 assembly sites [114], thus reducing the abil-
ity of the plasma membrane to retain fully released
Tetherin-containing virions. Interestingly, a recent study
provided evidence that partitioning of Vpu in lipid rafts
would be required to promote virus particle release
[129]. It will be important to determine whether Vpu
targets a pool of Tetherin located in specific microdo-
mains of the plasma membrane or whether the viral
antagonist targets the restriction factor independently of
its distribution at the plasma membrane.
Vpu, a versatile Tetherin antagonist
Several mechanisms have been proposed to explain how
Vpu can downregulate Tetherin from the cell surface
and as a result antagonize its antiviral activity on HIV-1
release. These include proteasomal or endo-lysosomal
degradation of the restriction factor and/or alteration of
its trafficking toward the cell surface, resulting in intra-
cellular sequestration. Although mechanistically distinct,
these modes of antagonism all rely on the ability of Vpu
to bind Tetherin since the restriction imposed by
Tetherin on viral particle release can be restored by
mutations disrupting their mutual association [130-134].
Such mutations have been all mapped so far to either
Vpu or Tetherin TM domains, thus strongly suggesting
that the two proteins associate through their respective
TM regions [131,132,135-137]. Evidence for each of the
proposed Vpu anti-Tetherin mechanisms are reviewed
and discussed below.
i) Vpu-mediated degradation of Tetherin
Vpu expression was found to decrease the total steady-
state levels of Tetherin [128,130,134,138,139]. This
depletion occurs at a post-transcriptional step since
levels of Tetherin transcript are not affected by Vpu
[130,134]. Importantly, pulse-chase experiments revealed
that Vpu accelerates the turnover of endogenous
Tetherin [130,131,139]. As observed with Vpu-mediated
CD4 degradation, recruitment of b-TrCP was found to
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since phosphorylation-deficient Vpu mutants did not
alter Tetherin turnover [130,131]. Likewise, siRNA-
mediated depletion of b-TrCP or inactivation of the
SCF
b-TrCP E3 Ub ligase by overexpression of a DN
mutant of b-TrCP, b-TrCPΔF, which binds Vpu but is
unable to link it to the SCF
b-TrCP E3 ligase complex,
abolished Vpu-mediated Tetherin degradation, indicat-
ing that recruitment of the SCF
b-TrCP complex is critical
for Vpu-mediated Tetherin degradation [128,130,
133,134]. In that regard, siRNA depletion experiments
revealed that Vpu takes specifically advantage of the cyto-
plasmic b-TrCP-2 isoform, but not the nuclear b-TrCP-1,
to achieve Tetherin degradation [128,130,133]. Finally,
complementing this set of functional evidence, b-TrCP
was found in a ternary complex together with Vpu and
Tetherin [133,134], but was not critical for the associa-
tion of Vpu to Tetherin [130].
This degradative process was initially thought to be
proteasomal in nature since long treatment with protea-
somal inhibitors prevented exogenously-expressed
Tetherin degradation in presence of Vpu in HEK 293T
cells [134,138-140]. Furthermore, overexpression of Ub
K48R, a DN mutant of Ub, which interferes with polyu-
biquitination, prevented Tetherin degradation [134].
Consistently, Vpu was found to promote the b-TrCP-
mediated ubiquitination of Tetherin cytoplasmic tail on
serine, threonine, lysine and cysteine residues at least in
HEK293T [141] (Figure 3B). Interestingly, depletion of
the ERAD component, AAA ATPase p97, affected Vpu-
mediated Tetherin degradation [134], suggesting that
Vpu could mediate Tetherin proteasomal degradation in
the ER through an ERAD-like process. However, there
are several caveats with the data supporting proteosomal
degradation. First, the results were often obtained by
overexpression of epitope tagged-Tetherin in non
restrictive HEK 293T cells, an experimental setting
which results in the accumulation of immature Tetherin
molecule within the endoplasmic reticulum [116]. Sec-
ond, long exposure with proteasome inhibitors or Ub
K48R overexpression are not always an unambiguous
evidence of ubiquitin-proteasome degradation since
these processes can deplete free Ub, thus affecting indir-
ectly Ub-dependent trafficking and/or lysosomal degra-
dation [142,143]. Accordingly, inhibitors of lysosomal
sorting and acidification, such as bafilomycin A and
concanamycin were found to inhibit Vpu-mediated
Tetherin degradation and could interfere with Tetherin
downregulation from the cell-surface [128,130]. This
type of degradation is indeed consistent with the recent
observation that Tetherin undergoes monoubiquitina-
tion on cytoplasmic lysines 18 and/or 21 in presence of
Vpu [144]. Taken together, these findings support a
model whereby Tetherin undergoes degradation in
lysosomes in presence of Vpu. However, proteasomal
degradation cannot be completely excluded, at this
point.
ii) Vpu-mediated intracellular sequestration of Tetherin
Although Vpu expression induces Tetherin degradation in
most cellular systems studied to date, several lines of evi-
dence suggest that degradation of Tetherin per se cannot
entirely account for Vpu-mediated Tetherin antagonism.
For instance, Vpu was found to decrease total cellular
Tetherin to a lesser extent than cell-surface Tetherin in
HeLa cells [128]. Furthermore, Vpu mutants that contain
mutations in the DS
PGFXS
P b-TrCP recognition motif
that render them deficient for directing b-TrCP-depen-
dent degradation of Tetherin are still able to partially
[39,42,128,130,134] or in some instances to totally
[24,102,103] overcome the Tetherin-mediated particle
release restriction. Moreover, Vpu-mediated Tetherin
degradation is a relatively slow process [130,131] (half-life
of ~8 h is decreased by ~2-fold in presence of Vpu) as
compared to the efficient CD4 receptor degradation
induced by Vpu (half-life of ~6 h is decreased by ~25-fold
in presence of Vpu [36]). There is now increasing evidence
for the existence of an anti-Tetherin mechanism that is
distinct from degradation of the restriction factor. In that
regard, recent evidence showed that Vpu did not promote
Tetherin endocytosis [128,131], but rather induced a re-lo-
calization of the antiviral factor to a perinuclear compart-
ment that extensively overlapped with the TGN marker,
TGN46, and Vpu itself, thus leading to a specific removal
of cell-surface Tetherin [131,144,145]. These findings are
indeed consistent with previous data showing that proper
distribution of Vpu in the TGN is critical to overcome
Tetherin restriction on HIV-1 release [29]. Overall, it
appears that Vpu may antagonize Tetherin, at least in
part, by sequestering the protein intracellularly through
alteration of its normal anterograde trafficking. Impor-
tantly, mutations of the putative Ub-acceptor lysine
residues, K18 and K21, in the cytosolic tail of Tetherin
(Figure 3B), completely abolished Vpu-mediated monoubi-
quitination [144] and degradation [140] of the restriction
factor without, however, affecting its antagonism by Vpu.
These findings provide genetic evidence that Tetherin ubi-
quitination/degradation and Tetherin antagonism may be
two separable Vpu activities. Moreover, since the lysine-
less Tetherin mutant was still found to be downregulated
at the cell surface in presence of Vpu, it appears that
Tetherin downregulation and ubiquitination/degradation
may not be as strictly linked during Vpu-mediated antag-
onism [140,144]. These unexpected results contrast, how-
ever, with previous data showing that Vpu mutants that
are unable to recruit b-TrCP (and as such are predicted to
be unable to mediate Tetherin ubiquitination/degrada-
tion), such as phosphorylation-deficient Vpu mutants, dis-
play an attenuated Tetherin antagonism (~50% of WT
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or expression of a DN mutant of b-TrCP, b-TrCPΔF,
could partially inhibit Vpu-mediated Tetherin antagonism
[128,130,134]. The recent results of Tokarev and collea-
gues indicating that b-TrCP-mediated polyubiquitination
of the Tetherin cytoplasmic tail specifically on serine and
threonine residues is critical for Vpu-mediated Tetherin
antagonism, while having little effect on the stability of the
restriction factor in presence of Vpu, might provide some
clues on the role b-TrCP on Tetherin antagonism. Based
on these results, it is indeed possible that Vpu-mediated
polyubiquitination of Tetherin via b-TrCP, might enhance
the sequestration of the restriction factor without necessa-
rily leading to Tetherin degradation [141]. Taken together,
these recent findings suggest that Tetherin antagonism by
Vpu precedes and may not be dependent on degradation
of the restriction factor, but rather results in the sequestra-
tion of Tetherin away from budding virions (Figure 5).
Clearly more studies are needed to evaluate the contribu-
tion of Tetherin ubiquitination and degradation in the
mechanism through which Vpu antagonizes the restriction
on HIV-1 particle release especially in cells that are natural
target for infection.
Although current evidence is consistent with a model
whereby antagonism of Tetherin by Vpu involves
sequestration of the restriction factor in a perinuclear
compartment, it is unclear whether Vpu subverts recy-
cling and/or other intracellular sorting steps of Tetherin.
Mutation of the overlapping Tyrosine (Tyr6 and Tyr8)
trafficking signals in the Tetherin cytoplasmic tail
(Figure 3B), which blocks the protein natural pathway of
endocytosis, did not abolish the sensitivity to Vpu in
non-restrictive cells (HEK 293T, HT1080) transiently
[131,133,145] or stably expressing the Tetherin mutant
[140]. Thus, it appears that Tetherin intracellular
sequestration may occur before endocytosis of the
restriction factor from the cell surface and as such
involve newly synthesized Tetherin en route to the PM
[131,133]. However, it cannot be ruled-out completely
that Vpu could interact with endocytosed Tetherin and
prevent its recycling back to the cell surface since pre-
vious data demonstrated a requirement for the recycling
endosomes in Vpu function [30], and recent studies
reported that AP2 depletion [128] or over-expression of
dominant DN mutant of Dynamin [133] could partially
interfere with Vpu-mediated downregulation of Tetherin
from the cell surface. Moreover, Tetherin is accumu-
lated in the presence of Vpu in structures just beneath
t h ep l a s m am e m b r a n et h a tc o u l dc o r r e s p o n dt oe a r l y
and/or recycling endosomes [114]. Indeed, since Vpu is
produced from a Rev-regulated gene expressed late dur-
ing the virus life cycle, the direct removal of Tetherin
from the plasma membrane via endosomal trafficking
may be critical to ensure a rapid and efficient neutraliza-
tion of Tetherin’s antiviral activity.
Tetherin, a common enemy
While HIV-1 Vpu was the first anti-Tetherin factor dis-
covered, there is now a growing list of virus-encoded pro-
teins harboring anti-Tetherin activities. Namely, KSHV
K5, HIV-2 Env, and Ebola gp were found to overcome
human Tetherin antiviral activity apparently through dis-
tinct mechanisms [98,99,144,147-149] (Table 1). Nef from
SIVcpz, SIVgor, SIVagm and SIVsmm, Env from SIVtan
(SIV from Tantalus monkey) and Vpu from SIVgsn, SIV-
mon and SIVmus were also reported to antagonize
Tetherin from their corresponding hosts [150-153]. Their
strategies differ, though. The KSHV K5 protein, which is a
membrane associated Ring-CH (MARCH) Ub ligase,
induces a species-specific downregulation of human
Tetherin from the cell surface by inducing ubiquitination
of Tetherin cytoplasmic lysines and targeting the restric-
tion factor to lysosomes for degradation [99,144]. In con-
trast, HIV-2 Env or SIVtan Env do not display any ability
to induce Tetherin degradation [145,147-149]. Instead,
these envelope proteins redistribute Tetherin from the
plasma membrane to a perinuclear compartment that
appears to correspond to the TGN most probably by a
sequestration mechanism [145,148,149]. However, in
contrast to Vpu, the determinants controlling Tetherin
Figure 5 Unified model of Vpu-mediated cell-surface Tetherin
downregulation. Tetherin traffics along the anterograde trafficking
pathway and reaches the plasma membrane. The protein is
endocytosed in clathrin-coated pits, transported to the TGN and
most probably recycles back to the cell surface. Upon expression of
Vpu, Tetherin is forming complexes with the viral protein, thus
trapping the restriction factor in the TGN, away from sites of viral
assembly at the plasma membrane where Tetherin is cross-linking
progeny virions. Vpu could intercept endocytosed Tetherin as well
as Tetherin arriving from the ER although this remains to be
determined. Subsequently, Vpu could induce Tetherin ubiquitination
through recruitment of b-TrCP-2, leading to a stronger retention in
the TGN. Sequestered ubiquitinated Tetherin conjugates could
ultimately be targeted for proteosomal and/or lysosomal
degradation. As such, Vpu-mediated Tetherin degradation may
represent a complementary mechanism that Vpu could exploit to
reach optimal Tetherin antagonism, perhaps, in specific cellular
environments.
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in the restriction factor ectodomain [148,149]. Studies on
HIV-2, SIVtan Env and KSHV K5 indicate that both
sequestration and degradation represent potent mechan-
isms by which Tetherin antiviral activity can be over-
comed. The fact that HIV-1 Vpu can exploit both
mechanisms confirms its great versatility and might per-
haps explain the efficient counteraction that it displays
against human Tetherin. Although the precise mechanism
underlying Tetherin antagonism by Nef remains to be
determined, it was found that SIVmac Nef downregulates
rhesus Tetherin from the cell surface and as shown for
Vpu-mediated Tetherin antagonism, this downregulation
correlated with enhanced SIVmac particle release
[150,152]. Finally, the antagonism of human Tetherin by
Ebola gp is still not entirely understood. The case of Ebola
gp is particularly interesting since it is the only known
anti-Tetherin factor that does not appear to downregulate
T e t h e r i nf r o mt h ec e l ls u r f a c et op r o m o t et h er e l e a s eo f
Ebola virus-like particle [147]. Even more surprising, inter-
action between Tetherin and Ebola gp would not require
any specific sequence, a feature that is unique among
Tetherin antagonists identified to date [147]. Therefore, it
appears that Ebola virus gp might use a novel mechanism
to neutralize Tetherin restriction. Clearly, comparative
studies of these anti-Tetherin viral factors will not only
further our understanding of their mechanisms of action
but will also provide key information on host cell pro-
cesses involved in Tetherin antagonism.
Role of Vpu in primate lentivirus cross-species
transmission and the emergence of pandemic
HIV-1 strains
Genes encoding for restriction factor, such as TRIM5-a,
APOBEC3G and Tetherin undergo rapid evolution, a pro-
cess also known as positive selection, most likely as the
result of the selective pressure imposed by new emerging
viral pathogens or to escape from viral antagonists during
the millions of years of virus-host co-evolution [154-156].
Consequently, these restriction factors display a high
degree of sequence divergence and constitute potent
limiting barriers to virus cross-species transmission
because viral antagonists usually function in a species-
specific manner. In fact, sequence alignment of Tetherin
from different primate species reveals important selective
genetic changes that lead to amino-acid substitution or
deletion primarily in the cytoplasmic and TM domains of
the protein, regions that are now known to be targeted by
Tetherin antagonists [138,156,157] (Figure 3B).
These genetic changes in Tetherin sequence have
shaped the evolution of primate lentiviruses and influ-
enced at least in part their ability to transmit across spe-
cies. There is evidence suggesting that SIVcpz, the
precursor of HIV-1, results from recombination events
between the precursors of the SIVgsn/mon/mus and the
SIV from red capped mangabeys (SIVrcm) lineages
[158] (Figure 6). The precursor of SIVgsn/mon/mus that
contributed to the 3’-half of the SIVcpz/HIV-1 genome,
most likely harbored a vpu gene product able to both
induce CD4 degradation and antagonize Tetherin since
all descendants do. Since it is believed that the ancestor
of the SIVrcm lineage used Nef to antagonize Tetherin,
given that this lineage does not encode a vpu gene, the
chimeric virus that gave rise to SIVcpz contained two
potential Tetherin antagonists. However, the SIVcpz
Vpu protein inherited from the SIVgsn/mon/mus line-
age is devoid of any activity against the chimpanzee and
human Tetherin [151,153,157].
The resistance displayed by the chimpanzee Tetherin
to the Vpu protein originating from the SIVgsn/mon/
mus lineage results from the high sequence variability in
the TM domain of Tetherin reported between non-
hominoid primates (monkeys such as rhesus or African
green monkey) and hominoid primates (such as chim-
panzees, gorillas and humans) [151,156,157] (Figure 1B).
Indeed, this TM domain was demonstrated to be the
site conferring Vpu susceptibility and binding
[131,132,136,138,156]. As a result Nef, and not Vpu,
evolved to become an effective Tetherin antagonist in
SIVcpz-infected chimpanzee, most likely because the
cytoplasmic domain sequence DDIWK targeted by Nef
is somewhat less divergent between chimpanzee and
Table 1 Anti-Tetherin mechanisms reported for the known Tetherin antagonists
Tetherin antagonists Binding Mechanisms References
HIV-1 Vpu Yes Proteosomal degradation [134,138,139]
Lysosomal degradation [128,130]
Sequestration in TGN and/or endosomes [131,145]
HIV-2 Env Yes Intracellular sequestration [145,148]
SIV Nef ? Increased internalization from the cell-surface? [150-152]
SIVtan Env ? Intracellular sequestration [149]
KSHV K5 ? Lysosomal degradation [99,144]
Ebola gp Yes ? [98,147]
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[150-153,157]. The deletion of sequences, highly sub-
jected to adaptation and recognized by Nef, in human
Tetherin is hypothesized to be the result of a previous
encounter with a viral pathogen during human evolution
that used a Nef-like protein, if not Nef itself, to antago-
nize Tetherin [157]. Conversely, few differences were
observed in the TM domain of Tetherin between chim-
panzee and human Tetherin, suggesting that Vpu has
not driven Tetherin adaptation for a long period in pri-
mate evolution and accounting for the ability of the
HIV-1 Vpu to counteract the chimpanzee Tetherin
[157] (Figure 3B).
The inability to use Nef as a human Tetherin antago-
nist following SIVcpz cross-species transmission to
human has likely led SIVcpz to proceed to a ‘’neofunc-
tionalization’’ of its initially incompetent Vpu protein in
order to efficiently overcome the restriction imposed by
human Tetherin (Figure 6). In support of this adaptation
mechanism, it was recently reported that the differential
ability of HIV-1 and SIVcpz Vpu to antagonize human
Tetherin could be mapped to two regions of the TM
domain of Vpu (amino-acid residues 1-8 and 14-22).
Importantly, SIVcpz Vpu was completely able to over-
come the human Tetherin restriction when these two
regions were substituted for those from HIV-1 Vpu
[157]. Furthermore, analysis of a SIVcpz strain (LB7)
that represents the closest relative to HIV-1 group M
revealed that the LB7 Vpu allele is predicted to need 7
minimal adaptations within these two critical regions of
the TM domain to gain the ability to antagonize human
Tetherin [157]. Consistent with these findings, mutagen-
esis of the prototypical NL4.3 Vpu TM domain identi-
fied three amino acid positions A14, W22 and, to a
lesser extent A18, as Vpu residues critical for Tetherin
binding and antagonism [135] (Figure 1B). Interestingly,
these residues are predicted to align on the same face of
the Vpu TM a-helix and as such might potentially be
part of the interface that directly or indirectly interacts
with the TM domain of human Tetherin.
The adaptation towards Vpu specifically shaped to
counteract the hominoid Tetherin is at the center of the
lineage-specific anti-Tetherin activity harbored by HIV-1
Vpu [138,151,156]. In line with this observation, substi-
tuting the TM domain of the human Tetherin with that
from African green monkey or rhesus monkey Tetherin
abrogated the chimeric protein sensitivity and binding
to HIV-1 Vpu [131,132,156]. Indeed, analysis of the resi-
dues within the TM domain of human Tetherin, which
determines the susceptibility to HIV-1 Vpu-mediated
antagonism, revealed that one single substitution muta-
tion for a residue found in the monkey Tetherin (T45I)
combined to a deletion of two amino acids (G25, I26),
absent from agm Tetherin, resulted in an efficient
restriction of wild-type HIV-1 [156]. More recently,
using a live cell based assay to monitor interaction,
Kobayashi and colleagues performed a detailed analysis
of the amino-acid residues within the TM domain of
human Tetherin that are involved in Vpu binding [136].
This study identified three amino acid residues (I34, L37
and L41) as critical determinants for Vpu interaction
and susceptibility [136] (Figure 3B). Furthermore, con-
sistent with previous studies [132,138,156,159], they
found that the integrity of the 22L-L-L-G-I26 amino acid
Figure 6 Adaptations of primate lentiviruses during cross-
species transmission and the emergence of pandemic HIV-1
strains. The SIV from chimpanzee is believed to result from
recombination events through successive cross-species transmission
between the precursors of the SIVgsn/mon/mus and the SIVrcm
lineages. The transmembrane domain of Tetherin evolved primarily
during transition from the non hominoïd lineage to the hominoïd
lineage, explaining why the Vpu protein inherited from the SIVgsn/
mon/mus lineage does not exhibit any activity against chimpanzee
Tetherin. After transmission from chimpanzees to humans, SIVcpz
was unable anymore to use Nef to counteract Tetherin due to a
deletion of five amino acids in the cytoplasmic domain of human
Tetherin, which usually confers responsiveness to Nef. During
evolution/adaptation from SIVcpz to HIV-1, modifications mapped to
two regions of the Vpu transmembrane domain have conferred
human Tetherin a susceptibility to Vpu, except in the case of the
HIV-1 group O. Furthermore, the HIV-1 group N Vpu somehow has
lost its ability to mediate CD4 degradation in the process. Only the
pandemic HIV-1 group M harbors the two primary Vpu functions.
Susceptibility of the transmembrane domain of Tetherin to Vpu is
represented by similar colour pairing. The deletion of the five amino
acids in human Tetherin cytoplamic tail is represented by the
absence of the D/GDIWK sequence. The color gradient indicates co-
evolution between SIV/HIV and host.
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amino acids in agm/rhesus Tetherins (deletion of L22,
L23 or L24, G25 or G25, I26, depending on the align-
ment), and/or conservation of a threonine at position 45
is required for the antagonism by Vpu (Figure 3B). On
the basis of computer-assisted structural modeling and
mutagenesis data, this study proposes that alignment of
amino-acids of I34, I37, L41 and T45 on the same heli-
cal face in the TM domain, a positioning apparently
governed by the presence of L22 and L23 (or perhaps
the integrity of the 22L-L-L-G-I26 amino-acid sequence),
is crucial for human Tetherin antagonism by Vpu. Intri-
guingly, while mutation at position T45 affected the
sensitivity of human Tetherin to Vpu, it did not signifi-
cantly affect the formation of a Tetherin-Vpu complex,
suggesting that interaction of Vpu to Tetherin alone is
not sufficient to mediate Tetherin antagonism. Further
studies will be necessary to address this potentially
important issue.
Phylogenetic analyses indicate that at least three inde-
pendent cross-species transmissions of SIVcpz gave rise
to HIV-1 group M (main), N (non-M, non-O) and O
(outlier) [160]. The functional properties acquired by
Vpu proteins during these three independent transmis-
sions of SIVcpz to humans have been recently analyzed
and shown to have perhaps determined the propensity of
these different groups to spread efficiently [151]. The
Vpu protein of the HIV-1 M group responsible for the
global HIV-1 pandemic was found to efficiently antago-
nize human Tetherin and to induce CD4 degradation. In
contrast, the non-pandemic HIV-1 group O Vpu was
found to have preserved its ability to mediate CD4 degra-
dation but displayed a very weak activity against human
Tetherin, while the rare HIV-1 group N gained some
anti-human Tetherin activity, but lost its ability to
degrade CD4 (Figure 6). These observations have led
Kirchhoff and colleagues to propose that the acquisition
of a fully competent Vpu protein able to antagonize
Tetherin and mediate CD4 degradation may have facili-
tated the global spread of the HIV-1 M group, as
opposed to the N and O groups whose distribution has
remained very limited and focused to West Africa [151].
Nevertheless, the fact that HIV-1 from the N and O
groups are still able to cause AIDS in infected individuals
suggests that Vpu-mediated CD4 degradation and
Tetherin antagonism may not be biological activities
required for HIV-1 dissemination within an infected indi-
vidual but rather functions that are critical for efficient
transmission between individuals. A similar parallel can
also be established with HIV-2, whose geographical dis-
tribution has been limited in comparison to HIV-1 [161].
As discussed previously, HIV-2 antagonizes human
Tetherin using its Env glycoprotein since its genome
does not encode a Vpu protein and its Nef protein
cannot counteract human Tetherin [145,148]. Interest-
ingly, HIV-2 Env was found to antagonize Tetherin less
efficiently than HIV-1 Vpu, perhaps, because its mode of
action solely involves a trapping of the restriction factor
in the TGN [148]. However, the fact that this virus uses a
structural protein to both downregulate CD4 (through
complex formation in the ER) and Tetherin, could have
also entailed a greater fitness cost to the virus than the
use of accessory proteins such as Vpu or Nef, thus
explaining in part its attenuated virulence in comparison
to HIV-1 [161]. Therefore, it will be interesting to assess
in the future whether Tetherin antagonism and/or CD4
degradation promote human-to-human HIV-1 transmis-
sion, perhaps by increasing the secretion of infectious
virions into the genital fluids.
Conclusions and perspectives
As molecular and cellular details about the mechanisms
through which Vpu mediates CD4 degradation and
antagonizes Tetherin emerge, it is becoming increasingly
clear that the acquisition of a multifunctional Vpu pro-
tein by HIV-1 has played a crucial role in the virulence of
this virus. Although the role of Vpu as an antagonist of
Tetherin has obvious implications on virus secretion and
potentially on the transmission efficiency from human to
human, its effect on the dissemination of HIV-1 follow-
ing establishment of infection is less clear, especially
since the potential restricting effect of Tetherin imposed
on cell-to-cell viral transmission does not appear to sig-
nificantly interfere with viral spread at least in T lympho-
c y t e s[ 1 2 4 ] .I ti sp o s s i b l et h a to n c ei n f e c t i o ni s
established in lymphoid tissue, such as the gut-associated
lymphoid tissue (GALT), a major site of HIV-1 replica-
tion, cell-to-cell transfer may be an important mode of
HIV-1 dissemination as opposed to a transmission via
cell-free virus. One might speculate that Tetherin antag-
onism by Vpu may be less critical at this point. More stu-
dies will be required in the future to address this issue
and to assess whether enhanced cell-to-cell transmission
might not be a way for HIV-1 to escape or even tolerate
Tetherin restriction. The contribution of Vpu-mediated
CD4 degradation to HIV-1 spread remains unclear and
will need to be further addressed. As discussed above,
previous studies have suggested that this function would
facilitate virion assembly by releasing Env precursor
gp160 trapped with newly synthesized CD4 in the ER and
maintain the release of fully infectious virions (reviewed
in [21]). In that regard, experiments using the simian-
human immunodeficiency virus (SHIV) model in pigtail
macaques, a host that does not express a Tetherin pro-
tein susceptible to HIV-1 Vpu, suggested that the ability
of Vpu to downregulation CD4 expression directly corre-
lated with the progression of disease in this animal model
[162,163]. Macaques inoculated with SHIV expressing a
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involved in the recruitment of b-TrCP did not show any
evidence of CD4+ T cell depletion and maintained signif-
icantly lower viral loads than macaques inoculated with
parental SHIV. These findings obtained in vivo suggest
that Vpu-mediated CD4 degradation may have an impor-
tant role in disease progression. However, we cannot
rule-out that Vpu may have additional functions that are
important for viral pathogenesis. In that regard, it is
interesting to note that a recent study reported a novel
activity of Vpu, that is the downregulation of CD1d at
the cell surface of infected DCs and the impairment of
CD1d-mediated natural killer T (NKT) cell activation
[164]. CD1d is a membrane-associated protein that is
expressed at the cell surface of antigen presenting cells
(APCs), such as monocytes, macrophages and DCs. This
protein is responsible for the presentation of exogenous
pathogen-induced lipid antigens to NKT cells expressing
an invariant abT cell receptor and in doing so triggers
the mutual activation of both APCs and NKT cells and
the subsequent induction of cellular immune responses.
Analysis of the mechanism of Vpu-mediated CD1d
downregulation revealed that Vpu does not enhance con-
stitutive endocytosis of CD1d nor induces its degrada-
t i o n .R a t h e r ,V p uw a sf o u n dt oi n t e r a c tw i t hC D 1 da n d
inhibit its recycling from endosomal compartments to
the plasma membrane by sequestering CD1d in an intra-
cellular compartment. Targeting of membrane-associated
surface proteins by Vpu does not appear to be limited to
CD4, Tetherin and CD1d since recent evidence indicates
that Vpu can also downregulate the NK-T and B cell
antigen (NTB-A) co-activator at the surface of infected
cells and as a result interferes with the degranulation of
NK cells [165]. NTB-A is type 1 membrane-associated
protein that belongs to the signaling lymphocytic activa-
tion molecules (SLAM) family of receptors that functions
as a homotypic ligand-activation NK receptor pair in the
induction of NK cell responses. Interestingly, NTB-A
downregulation by Vpu was found to be distinct from
CD4 and Tetherin downregulation since Vpu did not
alter the steady-state levels of NTB-A and did not rely on
the recruitment of b-TrCP to reduce cell surface NTB-A.
Like with CD1d and Tetherin, Vpu did not enhance
NTB-A endocytosis but rather appeared to interact with
co-activator molecules through its TM domain. These
findings suggest that Vpu might also downregulate NTB-
A through alteration of the protein trafficking and/or
recycling, which would lead to the sequestration of the
molecule in an intracellular compartment. Importantly,
Vpu-mediated downregulation of NTB-A was found to
interfere specifically with NK cell degranulation, thus
ultimately protecting infected cells from NK cell-
mediated lysis.
The fact that Vpu is now reported to target, in addi-
tion to CD4, three membrane-associated cell surface
proteins involved in various aspects of the innate
immune response raises the possibility that Vpu may be
a key factor used by HIV-1 to evade innate immunity.
While it may be too soon to call Vpu a virulence factor,
the recent discoveries presented in this review tend to
suggest that this accessory protein provides HIV-1 with
unique properties at the level of virus transmission and
escape from host defenses. Further research in these
areas will not only provide exciting new insight into the
role of Vpu in HIV-1 pathogenesis but may also lead to
new therapeutic interventions for treating HIV-1
infection.
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